Clinical trials: Thrombolytic (t-PA) Treatment
Acute Ischemic Stroke
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）
The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be…
- Trial name
- NCT05281549
- Testing
- Alteplase, Tenecteplase
- Where
- 28 sites in China
- Volunteers
- 225 people
- Sponsor
- Beijing Tiantan Hospital
Stroke, Acute
The Intravascular Cooling in the Treatment of Stroke 2/3 Trial
The purpose of this trial is to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.
- Trial name
- ICTuS2/3 (NCT01123161)
- Testing
- hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
- Where
- 31 sites in United States, Austria and 1 more
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Pulmonary Embolism
Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE) at intermediate risk, it is effective to…
- Trial name
- MONALYSE (NCT02604238)
- Testing
- Alteplase
- Sponsor
- Azienda U.S.L. 1 di Massa e Carrara
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Myocardial Infarction
A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)
The general aim of this study was to assess the feasibility of treating acute myocardial infarction (AMI) by physician-directed pre-hospital thrombosis, using accelerated alteplase (Actilyse®) and a diagnostic technique involving…
- Trial name
- PHARAOH (NCT02235389)
- Testing
- Alteplase (Actilyse), Standard therapy
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Embolism, Thrombophlebitis
Treatment for Blood Clots in the Veins of the Legs
Acute deep venous thrombosis (ADVT) of the lower extremity is a common disorder. Traditional treatment with anticoagulation therapy is effective in reducing the associated risk of pulmonary embolism, but is ineffective in…
- Trial name
- NCT00001713
- Testing
- Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Infarction, Middle Cerebral Artery
Thrombectomy Under Reopro Versus Alteplase to Treat Stoke
Intravenous (IV) Alteplase (rt-PA) is the gold standard for brain infarction within 4 h 30 of symptoms onset. Efficacy of this therapy is limited in the setting of large artery occlusions.
- Trial name
- TURANDOT (NCT02016547)
- Testing
- abciximab IV and thrombectomy, alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- SOS Attaque Cérébrale
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke, Acute
Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion
Iron overload has been associated with greater brain injury in ischemia/reperfusion experimental stroke models and ischemic stroke patients, especially in those treated with thrombolytic treatment.
- Trial name
- TANDEM-1 (NCT00777140)
- Testing
- Deferoxamine
- Where
- 4 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Germans Trias i Pujol Hospital
Ischemic Stroke
Tirofiban for Patients Treated With Alteplase
After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%.
- Trial name
- MR TEA (NCT03357133)
- Testing
- Tirofiban, Alteplase
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- Capital Medical University
Ischemic Stroke
Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
Patients presenting to the emergency department with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their…
- Trial name
- NCT03340493
- Testing
- Tenecteplase
- Where
- 28 sites in Australia, New Zealand
- Volunteers
- 300 people
- Sponsor
- Neuroscience Trials Australia
Stroke, Brain Ischemia
Early Administration of Aspirin in Patients With Acute Ischemic Stroke Treated With Systemic Thrombolysis
The aim of this study is to determine whether early administration of aspirin in acute ischemic stroke patients treated with systemic thrombolysis is safe and can improve outcomes due to decreasing the number of early…
- Trial name
- NCT02921360
- Testing
- acetylsalicylic acid
- Volunteers
- 120 people
- Sponsor
- City Clinical Hospital No. 67, Moscow, Russia
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Ischemic Stroke
Rt-PA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke
The purpose of this study is to determine the safety and feasibility of remote limb ischemic conditioning(RIC) in acute ischemic stroke patients who received r-tPA thrombolytic therapy.
- Trial name
- NCT03231384
- Testing
- Remote ischemic conditioning
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Capital Medical University
Thrombosis
Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins
This study will test the effectiveness of low-dose recombinant tissue plasminogen activator (rtPA, or alteplase) in dissolving blood clots in major arm or neck veins.
- Trial name
- NCT00055159
- Testing
- Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Ischemic Stroke
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV infusion of mutant pro-urokinase against…
- Trial name
- DUMAS (NCT04256473)
- Testing
- mutant pro-urokinase, Alteplase
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Erasmus Medical Center
Ischemic Stroke
Predictors of Outcome in t-PA Treated Stroke.
Stroke is among the most disabilitating diseases worldwide in terms of numbers affected and its consequences. A relatively new and well documented treatment of acute ischemic stroke today is tPA (tissue plasminogen activator…
- Trial name
- NCT01498042
- Where
- Norway
- Volunteers
- 162 people
- Sponsor
- Sorlandet Hospital HF
Pulmonary Thromboembolisms, Pulmonary Embolism
Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than the FDA-approved rt-PA 100mg/2h regimen…
- Trial name
- NCT01531829
- Testing
- Recombinant tissue plasminogen activator (rt-PA), Low Molecular Weight Heparin
- Where
- 35 sites in China
- Volunteers
- 460 people
- Sponsor
- Beijing Chao Yang Hospital
Pulmonary Embolism
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
- Trial name
- RESCUE (NCT04248868)
- Testing
- The Bashir™ Endovascular Catheter, r-tPA
- Where
- 19 sites in United States
- Volunteers
- 109 people
- Sponsor
- Thrombolex, Inc.
Ischemic Stroke, Stroke
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome…
- Conditions
- Ischemic Stroke, Stroke, Brain Infarction
- Trial name
- CLEAR-ER (NCT00894803)
- Testing
- Eptifibatide, rt-PA
- Where
- 20 sites in United States
- Volunteers
- 126 people
- Sponsor
- University of Cincinnati